tiprankstipranks
Advertisement
Advertisement
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
PremiumRatingsDenali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
11d ago
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
Premium
Ratings
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
13d ago
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
Premium
The Fly
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
13d ago
Denali Therapeutics regains full rights to DNL593
PremiumThe FlyDenali Therapeutics regains full rights to DNL593
2M ago
Denali Regains DNL593 Rights After Takeda Collaboration Ends
Premium
Company Announcements
Denali Regains DNL593 Rights After Takeda Collaboration Ends
2M ago
Denali Therapeutics Secures $200 Million Royalty Funding
Premium
Company Announcements
Denali Therapeutics Secures $200 Million Royalty Funding
2M ago
Denali Therapeutics price target raised to $41 from $34 at Stifel
PremiumThe FlyDenali Therapeutics price target raised to $41 from $34 at Stifel
2M ago
Denali Therapeutics price target raised to $32 from $29 at Baird
Premium
The Fly
Denali Therapeutics price target raised to $32 from $29 at Baird
2M ago
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
Premium
Ratings
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100